US30161Q1040
© BusinessWire
11.01.2026
EXEL
LISTED
NASDAQ
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis anticipates 2026 will be a significant year of clinical, regulatory and commercial progress as the company grows its current cabozanti...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2026
EXEL
LISTED
NASDAQ
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
News Preview
Exelixis, Inc. (Nasdaq: EXEL) and Natera (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced their collaboration on the planned Exelixis-sponsored STELLAR-316 trial. This randomized phase 3 pivotal trial will evaluate zanzalintinib, Exelixis’ novel oral kinase inhibitor, with and without an immune checkpoint in...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
EXEL
LISTED
NASDAQ
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 5:15 p.m. PT / 8:15 p.m. ET.
To access the webcast link, log onto www.exelixis.com and proceed to the E...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
03.12.2025
EXEL
LISTED
NASDAQ
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast its virtual event, Exelixis 2025 R&D Day: Building Next-generation Oncology Franchises, on Wednesday, December 10, 2025, from 1:00 p.m. to 3:30 p.m. EST. During the event, featured speakers will review the progress of Exelixis’ R&D activities and outline the company’s strat...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
06.11.2025
EXEL
LISTED
NASDAQ
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November:
Guggenheim 2nd Annual Healthcare Innovation Conference: Exelixis is scheduled to present at 10:30 a.m. ET / 7:30 a.m. PT on Monday, November 10 in Boston.
Stifel 2025 Healthcare Conference:...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
EXEL
LISTED
NASDAQ
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones.
“In the third quarter of 2025, Exelixis gained momentum in the cabozantinib franchise and delivered on cr...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2025
EXEL
LISTED
NASDAQ
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
News Preview
Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
EXEL
LISTED
NASDAQ
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). As previously announced, the stud...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2025
EXEL
LISTED
NASDAQ
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX® (cabozantinib) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) originating in the lungs or thymus. These data will be presented at the 2025 European Society for Medical On...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
EXEL
LISTED
NASDAQ
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or “the Company”) (NASDAQ: EXEL) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disc...
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2025
EXEL
LISTED
NASDAQ
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced it has appointed Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. In this new role, Dr. Aftab will oversee all aspects of the company’s drug discovery, translational research, product development and medical affairs activities.
"Dana has been an integral part of the Ex...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2025
EXEL
LISTED
NASDAQ
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September:
2025 Wells Fargo Healthcare Conference: Exelixis is scheduled to present at 12:45 p.m. ET / 9:45 a.m. PT on Wednesday, September 3 in Everett, MA.
Citi’s 2025 Biopharma Back to School Co...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
28.07.2025
EXEL
LISTED
NASDAQ
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones.
“Exelixis continued to execute on our corporate objectives in the second quarter of 2025, delivering on...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
EXEL
LISTED
NASDAQ
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) for the treatment of adult patients with unresectable or metastatic, well-differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least o...
Themefolio
Profiler
Peergroup
© BusinessWire
14.07.2025
EXEL
LISTED
NASDAQ
Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025
News Preview
Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2025 financial results will be released on Monday, July 28, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available vi...
Themefolio
Profiler
Peergroup
© PR Newswire
08.07.2025
EXEL
LISTED
NASDAQ
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
News Preview
Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, July 8, 2025 /CNW/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government...
Themefolio
Profiler
Peergroup
© BusinessWire
22.06.2025
EXEL
LISTED
NASDAQ
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously t...
Themefolio
Profiler
Peergroup
© BusinessWire
20.06.2025
EXEL
LISTED
NASDAQ
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for CABOMETYX® (cabozantinib) for adult patients with unresectable or metastatic, well-differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroen...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
EXEL
LISTED
NASDAQ
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with either nivolumab (Opdivo®) or a fixed-dose combination of nivolumab and relatlimab (Opdualag™) in patients with previously untreated advanced clear cell renal cell carcinoma (RCC). These fi...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
EXEL
LISTED
NASDAQ
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May and June:
TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA: Exelixis is scheduled to present virtually at 2:30 p.m. ET / 11:30 a.m. PT on Tuesday, May 27.
William Blair...
Themefolio
Profiler
Peergroup
© BusinessWire
13.05.2025
EXEL
LISTED
NASDAQ
Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones.
“Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by acceleratin...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
EXEL
LISTED
NASDAQ
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May:
BofA Securities 2025 Health Care Conference: Exelixis is scheduled to present at 1:40 p.m. ET / 10:40 a.m. PT on Wednesday, May 14 in Las Vegas.
RBC Capital Markets 2025 Global Healthcare Confer...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
EXEL
LISTED
NASDAQ
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
News Preview
Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2025 financial results will be released on Tuesday, May 13, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
EXEL
LISTED
NASDAQ
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET); and...
Themefolio
Profiler
Peergroup
© BusinessWire
25.03.2025
EXEL
LISTED
NASDAQ
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced that preclinical data will be presented for four pipeline molecules at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30 in Chicago, IL.
“We are excited to share preclinical data from four of our pipeline molecules that constitute the next phase in our co...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
EXEL
LISTED
NASDAQ
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March:
TD Cowen 45th Annual Health Care Conference: Exelixis is scheduled to present at 9:50 a.m. ET / 6:50 a.m. PT on Tuesday, March 4 in Boston.
Barclays 27th Annual Global Healthcare Conference:...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
EXEL
LISTED
NASDAQ
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to an additional $500 million of the company’s common stock before December 31, 2025.
Exelixis plans on completing the currently ongoing $500 million stock repurchase program (SRP), announced in August 2024, in the second quarte...
Themefolio
Profiler
Peergroup
© BusinessWire
15.02.2025
EXEL
LISTED
NASDAQ
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating CABOMETYX® (cabozantinib) in combination with Opdivo® (nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma (RCC). After more than five years of follow-up, the findings demonstrated that e...
Themefolio
Profiler
Peergroup
© BusinessWire
13.02.2025
EXEL
LISTED
NASDAQ
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Citi 2025 Virtual Oncology Leadership Summit on Wednesday, February 19 at 2:00 p.m. ET / 11:00 a.m. PT.
To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News headin...
Themefolio
Profiler
Peergroup
© BusinessWire
11.02.2025
EXEL
LISTED
NASDAQ
Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones.
“Exelixis delivered a strong fourth quarter of 2024, positioning us well to maximize su...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2025
EXEL
LISTED
NASDAQ
Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
News Preview
Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2024 financial results will be released on Tuesday, February 11, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the ev...
Themefolio
Profiler
Peergroup
© BusinessWire
25.01.2025
EXEL
LISTED
NASDAQ
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-001 trial evaluating zanzalintinib alone or in combination with atezolizumab (Tecentriq®) in patients with previously-treated metastatic colorectal cancer (CRC). The findings will be presented during Poster Session C: Cancers of the Colon, Rect...
Themefolio
Profiler
Peergroup
© BusinessWire
24.01.2025
EXEL
LISTED
NASDAQ
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine tumors (epNET) arising in the gastrointestinal (GI) tract. The analysis showed cabozantinib was associated with an improvement in progression-free survival (PFS) compared with placebo...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2025
EXEL
LISTED
NASDAQ
Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2024, provided financial guidance for fiscal year 2025 and delivered an update on its business. Exelixis anticipates 2025 will be a year of clinical and regulatory execution and continued growth for its cabozantinib franchise, as well as m...
Themefolio
Profiler
Peergroup
© BusinessWire
09.01.2025
EXEL
LISTED
NASDAQ
Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic (epNET) will no longer b...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2025
EXEL
LISTED
NASDAQ
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 5:15 p.m. PT / 8:15 p.m. PT.
To access the webcast link, log onto www.exelixis.com and proceed t...
Themefolio
Profiler
Peergroup
© BusinessWire
27.11.2024
EXEL
LISTED
NASDAQ
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in December:
Piper Sandler 36th Annual Healthcare Conference: Exelixis is scheduled to present at 8:30 a.m. ET / 5:30 a.m. PT on Tuesday, December 3 in New York City.
Citi 2024 Global Healthcare Confe...
Themefolio
Profiler
Peergroup
© BusinessWire
26.11.2024
EXEL
LISTED
NASDAQ
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will b...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
EXEL
LISTED
NASDAQ
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November:
Guggenheim’s Inaugural Healthcare Innovation Conference: Exelixis is scheduled to present at 9:00 a.m. ET / 6:00 a.m. PT on Tuesday, November 12 in Boston.
Stifel 2024 Healthcare Conference...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2024
EXEL
LISTED
NASDAQ
Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial, clinical and pipeline development milestones.
“The favorable ruling on our cabozantinib intellectual property estate and recentl...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2024
EXEL
LISTED
NASDAQ
Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
News Preview
Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2024 financial results will be released on Tuesday, October 29, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2024
EXEL
LISTED
NASDAQ
Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. District Court for the District of Delaware ruled in Exelixis’ favor, rejecting MSN’s challenge to three Orange Book-listed patents related to cabozantinib...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2024
EXEL
LISTED
NASDAQ
Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
News Preview
Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the companies have entered into a clinical development collaboration to evaluate the combination of Exelixis’ investigational tyrosine kinase inhibitor (TKI) zanzalintinib with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrol...
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2024
EXEL
LISTED
NASDAQ
Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced updated and final data from CABINET, a phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) versus placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort with advanced pancreatic neuroendocrine tumors (pNET) and one cohort with advanced extra-pancreatic NET (...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2024
EXEL
LISTED
NASDAQ
Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced detailed final overall survival (OS) results from CONTACT-02, a phase 3 pivotal study evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab (Tecentriq®) compared with a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and measu...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2024
EXEL
LISTED
NASDAQ
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September:
Morgan Stanley 22nd Annual Global Healthcare Conference: Exelixis is scheduled to present at 9:15 a.m. ET / 6:15 a.m. PT on Wednesday, September 4 in New York City.
2024 Wells Fargo Heal...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
